Abstract
Background: Fibrolamellar Carcinoma (FLC) and Combined Hepatocellular- Cholangiocarcinoma (CHC) are rare primary liver tumours, which are related to different clinical settings. In both tumours, correlation with clinical data and laboratory tests are extremely important.
Discussion: Typically, FLC is diagnosed in young patients without any chronic disease and with normal biochemical tests, whereas CHC arises in cirrhotic patients with elevated tumour markers: AFP and/or CA 19-9.
The review describes epidemiology, aetiology, pathogenesis, radiological features and treatment of these tumours.
Imaging features typical for FLC are: The presence of central scar, calcifications, the large size, heterogeneous and early contrast-enhancement.
Conclusion: The diagnosis of CHC may be suggested in case of elevation of both AFP and CA 19- 9 or inconsistency between elevated tumour markers and imaging findings (i.e., elevated CA 19-9 and radiological features of HCC, or elevated AFP with imaging findings characteristic of ICC).
Keywords: Fibrolamellar carcinoma, combined hepatocellular-cholangiocarcinoma, primary hepatic tumors, hepatobiliary contrast agents, computed tomography, magnetic resonance imaging.
Graphical Abstract
[1]
Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of the liver in infancy and childhood. Am J Dis Child 1956; 91(2): 168-86.
[2]
Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinicopathologic features. Cancer 1980; 46: 372-9.
[3]
Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 1988; 19(7): 784-94.
[4]
Terzis I, Haritanti A, Economou I. Fibrolamellar hepatocellular carcinoma: A case report with distinct radiological features. J Gastrointest Cancer 2010; 41(1): 2-5.
[5]
Liu S, Wah Chan K, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: A case report and a summary of recent literature. QJM 2011; 104(6): 477-83.
[6]
Sooklim K, Sriplung H, Piratvisuth T. Histologic subtypes of hepatocellular carcinoma in the southern Thai population. Asian Pac J Cancer Prev 2003; 4(4): 302-6.
[7]
El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A U.S. population-based study. Hepatology 2004; 39(3): 798-803.
[8]
Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 2009; 104(10): 2617-24.
[9]
Górnicka B, Ziarkiewicz-Wróblewska B, Wróblewski T, et al. Carcinoma, a fibrolamellar variant - immunohistochemical analysis of 4 cases. Hepatogastroenterology 2005; 52: 519-23.
[10]
Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J, Maldonaldo H, Bornstein-Quevedo L. Fibrolamellar hepatocellular carcinoma in Mexican patients. Pathol Oncol Res 2002; 8(2): 133-7.
[11]
Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007; 14(3): 217-23.
[12]
Meriggi F, Forni E. Surgical therapy of hepatic fibrolamellar carcinoma. Ann Ital Chir 2007; 78(1): 53-8.
[13]
Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: Imaging and pathologic findings in 31 recent cases. Radiology 1999; 213(2): 352-61.
[14]
McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kshitani N, Ros PR. Fibrolamellar carcinoma of the liver: Radiologicpathologic correlation. Radiographics 1999; 19(2): 453-71.
[15]
Ganeshan D, Szklaruk J, Kundra V, Kaseb A, Rashid A, Elsayes KM. Imaging features of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol 2014; 202(3): 544-52.
[16]
Tanaka K, Honna T, Kitano Y, et al. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: A case report. J Clin Pathol 2005; 58(8): 884-7.
[17]
Malouf GG, Brugieres L, Le Deley MC, et al. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer 2012; 118(20): 4981-90.
[18]
Khoo JJ, Clouston A. Fibrolamellar hepatocellular carcinoma: A case report. Malays J Pathol 2001; 23(2): 115-8.
[19]
Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: Diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol 2016; 14(1): 151.
[20]
Do RK, McErlean A, Ang CS, DeMatteo RP, Abou-Alfa GK. CT and MRI of primary and metastatic fibrolamellar carcinoma: A case series of 37 patients. Br J Radiol 2014; 87(1040): 20140024.
[21]
Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: Comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005; 18(11): 1417-23.
[22]
Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003; 97(8): 2006-12.
[23]
Ichikawa T, Federle MP, Grazioli L, Marsh W. Fibrolamellar hepatocellular carcinoma: Pre- and posttherapy evaluation with CT and MR imaging. Radiology 2000; 217(1): 145-51.
[24]
Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006; 106(6): 1331-8.
[25]
Sarode VR, Castellani R, Post A. Fine-needle aspiration cytology and differential diagnoses of fibrolamellar hepatocellular carcinoma metastatic to the mediastinum: case report. Diagn Cytopathol 2002; 26(2): 95-8.
[26]
Montero A, Allende H, Tallada N, Ramon y Cajal S, Margarit C, Viladomiu L. Fine needle aspiration cytology of massive bilateral ovarian metastasis of fibrolamellar hepatocellular carcinoma. Acta Cytol 2007; 51(4): 682-3.
[27]
Kutluk MT, Yalçin B, Büyükpamukçu N, et al. Fibrolamellar hepatocellular carcinoma with skeletal metastases. Pediatr Hematol Oncol 2001; 18(4): 273-8.
[28]
Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg 2012; 215(6): 820-30.
[29]
Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Vol.3, Lyon 2010.
[30]
Blachar A, Federle MP, Ferris JV, et al. Radiologists’ performance in the diagnosis of liver tumors with central scars by using specific CT criteria. Radiology 2002; 223(2): 532-9.
[31]
Ichikawa T, Federle MP, Grazioli L, Marsh W. Fibrolamellar hepatocellular carcinoma: Pre- and posttherapy evaluation with CT and MR imaging. Radiology 2000; 217(1): 145-51.
[32]
Pedrassa BC, da Rocha EL, Kierszenbaum ML, et al. Uncommon hepatic tumors: Iconographic essay-Part 1. Radiol Bras 2014; 47(5): 310-6.
[33]
De Gaetano AM, Nure E, Grossi U, et al. Fibrolamellar hepatocellular carcinoma with biliary tumor thrombus: An unreported association. Jpn J Radiol 2013; 31(10): 706-12.
[34]
McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kshitani N, Ros PR. Fibrolamellar carcinoma of the liver: Radiologic-pathologic correlation. Radiographics 1999; 19(2): 453-71.
[35]
Liu S, Wah Chan K, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: A case report and a summary of recent literature. QJM 2011; 104(6): 477-83.
[36]
von Falck C, Rodt T, Shin HO, Knapp WH, Galanski M. F-18 FDG PET imaging of fibrolamellar hepatocellular carcinoma. Clin Nucl Med 2008; 33(9): 633-4.
[37]
Campos JT, Sirlin CB, Choi JY. Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: The atlas. Insights Imaging 2012; 3(5): 451-74.
[38]
Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195(1): 13-28.
[39]
Park MJ, Kim YK, Park HJ, Hwang J, Lee WJ. Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: Emphasis on the differentiation of intrahepatic cholangiocarcinoma. J Comput Assist Tomogr 2013; 37(6): 872-81.
[40]
Brancatelli G, Federle MP, Grazioli L, Blachar A, Peterson MS, Thaete FL. Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients. Radiology 2001; 219(1): 61-8.
[41]
Vilgrain V, Boulos L, Vullierme MP, Denys A, Terris B, Menu Y. Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics 2000; 20(2): 379-97.
[42]
Rousseau C, Ronot M, Sibileau E, et al. Central element in liver masses, helpful, or pitfall? Abdom Imaging 2015; 40(6): 1904-25.
[43]
Shetty AS, Fowler KJ, Brunt EM, Agarwal S, Narra VR, Menias CO. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 2014; 39(2): 310-22.
[44]
Maximin S, Ganeshan DM, Shanbhogue AK, et al. Current update on combined hepatocellular-cholangiocarcinoma. Eur J Radiol Open 2014; 1: 40-8.
[45]
Willekens I, Hoorens A, Geers C, Op de Beeck B, Vandenbroucke F, de Mey J. Combined hepatocellular and cholangiocellular carcinoma presenting with radiological characteristics of focal nodular hyperplasia. World J Gastroenterol 2009; 15(31): 3940-3.
[46]
Yin X, Zhang BH, Qiu SJ, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: Clinical features, treatment modalities, and prognosis. Ann Surg Oncol 2012; 19(9): 2869-76.
[47]
Lin G, Toh CH, Wu RC, et al. Combined hepatocellular cholangiocarcinoma: Prognostic factors investigated by computed tomography/magnetic resonance imaging. Int J Clin Pract 2008; 62(8): 1199-205.
[48]
de Campos RO, Semelka RC, Azevedo RM, et al. Combined hepatocellular carcinoma-cholangiocarcinoma: Report of MR appearance in eleven patients. J Magn Reson Imaging 2012; 36(5): 1139-47.
[49]
Nayyar M, Imagawa DK, Tirkes T, et al. Composite liver tumors: A radiologic-pathologic correlation. Clin Mol Hepatol 2014; 20(4): 406-10.
[50]
Fowler KJ, Sheybani A, Parker RA III, et al. Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: Imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 2013; 201(2): 332-9.
[51]
Hwang J, Kim YK, Park MJ, et al. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2012; 36(4): 8.
[52]
Schiettecatte A, Dujardin M, de Beeck BO, de Mey J. Combined hepatocellular-cholangiocarcinoma: MR findings. European Journal of Radiology Extra 2008; 67: 75-7.
[53]
Zhou YM, Yang JM, Wang B, Xu F, Tong Y, Li DQ. Combined hepatocellular carcinoma and cholangiocarcinoma: A case report and review of the literature. Hepatobiliary Pancreat Dis Int 2007; 6(6): 656-9.
[54]
Nishie A, Yoshimitsu K, Asayama Y, et al. Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: Comparison with histologic findings. AJR Am J Roentgenol 2005; 184(4): 1157-62.
[55]
Joo I, Kim H, Lee JM. Cancer Stem cells in primary liver cancers: Pathological concepts and imaging findings. Korean J Radiol 2015; 16(1): 50-68.
[56]
Meriggi F, Forni E. Surgical therapy of hepatic fibrolamellar carcinoma. Ann Ital Chir 2007; 78(1): 53-8.
[57]
Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: Demographic, clinical, and prognostic factors. Cancer 2002; 94(7): 2040-6.
[58]
Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: A clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003; 33(6): 283-7.
[59]
Zhou YM, Zhang XF, Wu LP, Sui CJ, Yang JM. Risk factors for combined hepatocellular-cholangiocarcinoma: A hospital-based case-control study. World J Gastroenterol 2014; 20(35): 12615-20.
[60]
Theise ND, Yao JL, Harada K, et al. Hepatic ‘stem cell’ malignancies in adults: Four cases. Histopathology 2003; 43(3): 263-71.
[61]
Koh KC, Lee H, Choi M, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 2005; 189(1): 120-5.
[62]
Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: Clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 2006; 13(6): 537-42.
[63]
Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract 2008; 62(8): 1271-8.
[64]
Toh CH, Cheung YC, Ng SH, Lin CY, Chan SC, Ng KK. Combined hepatocellular-cholangiocarcinoma: A case report. Int J Clin Pract 2004; 58(12): 1170-3.
[65]
Lee CC, Wu CY, Chen JT, Chen GH. Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: A clinicopathological study. Hepatogastroenterology 2002; 49(48): 1487-90.
[66]
Tang D, Nagano H, Nakamura M, et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular carcinoma and cholangiocarcinoma: A comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 2006; 10(7): 987-98.
[67]
Sanada Y, Shiozaki S, Aoki H, Takakura N, Yoshida K, Yamaguchi Y. A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma Assessment of Enhancement patterns on dynamics computed tomography before resection. Hepatol Res 2005; 32(3): 185-95.
[68]
Aoki K, Takayasu K, Kawano T, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: Clinical features and computed tomographic findings. Hepatology 1993; 18(5): 1090-5.
[69]
Shin CI, Lee JM, Kim SH, et al. Recurrence patterns of combined hepatocellular-cholangiocarcinoma on enhanced computed tomography. J Comput Assist Tomogr 2007; 31(1): 109-15.
[70]
Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234(2): 468-78.
[71]
Liu CL, Fan ST, Lo CM, et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg 2003; 138(1): 86-90.
[72]
Panjala C, Senecal DL, Bridges MD, et al. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular- cholangiocarcinoma. Am J Transplant 2010; 10(5): 1263-7.
Call for Papers in Thematic Issues
01 August, 2024
Intelligent Information Retrieval for Multispectral and Hyperspectral Imaging
Multispectral and hyperspectral imaging is an interdisciplinary research area, widely focuses on spectral, spatial, and temporal data. It offers a plethora of opportunities to efficiently analyze the vast area of the earth's surface. However, there are numerous factors such as dimensionality and size of the hyperspectral data, lesser training samples, ...read more
18 May, 2024
Machine and Deep Learning in Medical Image Diagnosis
Medical Image Processing regards a set of methodologies that have been developed over recent years with the purpose of improving medical image quality, improving medical data visualization, understanding, and assisting medical diagnosis, and so on. The application of machine and deep learning methods in sensing and imaging can potentially have ...read more
03 September, 2024
Quantum Machine Learning for Medical Data and Imaging
Quantum computing has promised a significant speedup in certain computationally intensive tasks that are intractable on classical computers. Researchers in quantum machine learning, such as those working in computer vision, image processing, biomedical analysis, and related topics, may play an important role in comprehending and working on complicated medical data, ...read more
Article Metrics
46
3